Tumors of female reproductive systemTumors of female reproductive systemОпухоли женской репродуктивной системы1994-40981999-8627Publishing House ABV Press14410.17650/1994-4098-2011-0-1-56-62MAMMOLOGY. TREATMENTМАММОЛОГИЯ. ЛЕЧЕНИЕAchievement of complete morphological regression in the use of trastuzumab in patients with inoperable locally advanced Her-2+ breast cancerДостижение полной морфологической регрессии при применении трастузумаба у больных неоперабельным местно-распространенным Her-2+ раком молочной железыZeinalovaK. R.ЗейналоваК. Р.
Russian Federation
kamka80@yahoo.comVishnevskayaYa. V.ВишневскаяЯ. В.
Russian Federation
GanshinaI. P.ГаньшинаИ. П.
Russian Federation
N.N. Blokhin Russian Cancer Research Cancer, Russian Academy of Medical Sciences, MoscowРОНЦ им. Н.Н. Блохина РАМН, Москва250220111566225072014250720142011https://ojrs.abvpress.ru/ojrs/article/view/144

Objective: to evaluate the efficiency (morphological tumor complete regression (mCR), a clinical effect) and safety of the use of new anthracycline-free neoajuvant chemotherapy regimens (paclitaxel + vinorelbine and docetaxel + carboplatin) in combination with trastuzumab in patients with Stage IIIa-c breast cancer (BC) and Her-2 hyperexpression.Subjects and methods. The study enrolled 36 Stage IIIa–c BC patients receiving 4–8 cycles of a chemotherapy regimen of paclitaxel (100 mg/m2) + vinorelbine (25 mg/m2) (every 3 weeks) or docetaxel (50 mg/m2) + carboplatin (AUC 5) (every 3 weeks) in combination with trastuzumab.Results. The docetaxel (75 mg/m2) + carboplatin (AUC 5) + trastuzumab regimen demonstrated a high effectiveness with acceptable toxicity. Seventeen (58.8 %) patients achieved mCP. The clinical effect was 83.3 % (4 complete and 11 partial tumor regressions).The paclitaxel (135 mg/m2) + vinorelbine (25 mg/m2) (every 3 weeks) + trastuzumab regimen is efficacious and promising when the doses of the drugs are increased and granulocyte colony-stimulating factor used.

Her-2 hyperexpressiontrastuzumabneoajuvant chemotherapy for breast cancerгиперэкспрессия Her-2трастузумабнеоадъювантная терапия рака молочной железы1. Jukkola A., Bloigu R., Soini Y. et al. c-erbB-2 positivity is a factor for poor prognosis in breast cancer and poor response to hormonal or chemotherapy treatment in advanced disease. Eur J Cancer 2001;37:347–54.Jukkola A., Bloigu R., Soini Y. et al. c-erbB-2 positivity is a factor for poor prognosis in breast cancer and poor response to hormonal or chemotherapy treatment in advanced disease. Eur J Cancer 2001;37:347–54.2. Prati R., Apple S.K., He J. et al. Histopathologic characteristics predicting Her-2/neu amplification in breast cancer. Breast J 2005;11:433–9.Prati R., Apple S.K., He J. et al. Histopathologic characteristics predicting Her-2/neu amplification in breast cancer. Breast J 2005;11:433–9.3. Carlomagno C., Perrone F., Gallo C. et al. C-erbB-2 overexpression decreases the benefit of adjuvant Tamoxifen in early-stage breast cancer without ancillary lymph node metastases. J Clin Oncol 1996;14:2702–8.Carlomagno C., Perrone F., Gallo C. et al. C-erbB-2 overexpression decreases the benefit of adjuvant Tamoxifen in early-stage breast cancer without ancillary lymph node metastases. J Clin Oncol 1996;14:2702–8.4. Ferrero-Pou ̈s M., Hacène K., Bouchet C. et al. Relationship between c-erbB-2 and other tumor characteristics in breast cancer prognosis. Clin Cancer Res 2000;6:4745–54.Ferrero-Pou ̈s M., Hacène K., Bouchet C. et al. Relationship between c-erbB-2 and other tumor characteristics in breast cancer prognosis. Clin Cancer Res 2000;6:4745–54.5. Gianni L., Semiglazov V., Manikhas G.M. et al. Neoadjuvant trastuzumab in locally advanced breast cancer: A randomized phase III trial with a parallel Her-2-negative cohort (the NOAH trial). Eur J Cancer 2008–2009. 6. Mehta R.S., Hsiang D., Lane K. et al. Association between pathologic complete response and survival in patients treated with sequential anthracyclines and concomitant taxanes and trastuzumab in Her-2-positive breast cancer. Cancer Res 2009;69 (2 Suppl): 3141.Gianni L., Semiglazov V., Manikhas G.M. et al. Neoadjuvant trastuzumab in locally advanced breast cancer: A randomized phase III trial with a parallel Her-2-negative cohort (the NOAH trial). Eur J Cancer 2008–2009. 6. Mehta R.S., Hsiang D., Lane K. et al. Association between pathologic complete response and survival in patients treated with sequential anthracyclines and concomitant taxanes and trastuzumab in Her-2-positive breast cancer. Cancer Res 2009;69 (2 Suppl): 3141.7. Slamon D., Eiermann W., Robert N. et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC3T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC3TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her-2 positive early breast cancer patients: BCIRG 006 study. Breast Cancer Res Treat 2005;94(Suppl 1):5.Slamon D., Eiermann W., Robert N. et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC3T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC3TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her-2 positive early breast cancer patients: BCIRG 006 study. Breast Cancer Res Treat 2005;94(Suppl 1):5.8. Slamon D., Eiermann W., Robert N. et al. BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC/ET) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC/ETH) with docetaxel carboplatin and trastuzumab (TCH) in Her- 2/neu positive early breast cancer patients. 29th Annual San Antonio Breast Cancer Symposium, December 14–17, 2006, San Antonio, Texas; abstr 52.Slamon D., Eiermann W., Robert N. et al. BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC/ET) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC/ETH) with docetaxel carboplatin and trastuzumab (TCH) in Her- 2/neu positive early breast cancer patients. 29th Annual San Antonio Breast Cancer Symposium, December 14–17, 2006, San Antonio, Texas; abstr 52.9. Chevallier B., Roche H., Olivier J.P. et al. Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC- HD) results in a high histologic response rate. Am J Clin Oncol 1993;16:223–8.Chevallier B., Roche H., Olivier J.P. et al. Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC- HD) results in a high histologic response rate. Am J Clin Oncol 1993;16:223–8.